Insecticides India Ltd. Overview
Insecticides (India) Limited is a Delhi-headquartered, promoter-controlled, fully integrated Indian crop-protection company. It describes itself as a crop protection and nutrition company. It manufactures more than 20 technical-grade active ingredients and more than 130 branded formulations across insecticides, herbicides, fungicides, biologicals and plant-growth regulators. These are sold mainly under the four-decade-old "Tractor Brand" through 8,500+ distributors and about 70,000 retailers, reaching an estimated 7.5 million farmers. FY2026 revenue was INR 2,140 crore. That makes IIL a mid-tier domestic generics-plus-specialty player, roughly the size of Dhanuka Agritech and smaller than Rallis, PI, UPL or Bayer CropScience India. Its strategy rests on three levers. The first is "premiumisation": in-licensed patented molecules from Nissan Chemical (Japan) and Corteva Agriscience (USA), branded "Maharatna". The second is backward integration into technicals at Chopanki and Dahej. The third is an FMCG-style rural distribution model. Its main vulnerabilities are monsoon dependence, a long working-capital cycle, and a modest export base (~5% of sales).
What the company does
IIL develops, registers, manufactures and markets agrochemicals for Indian farmers, with a smaller institutional and export business. The value chain runs from technical synthesis (making the active ingredient) through formulation (turning the active ingredient into usable liquids, powders and granules), branding, distribution and farmer extension. The company says about 95% of its revenue comes from products it manufactures itself (Q1 FY27 investor presentation).
Company's own description (paraphrased from FY26/Q1 FY27 disclosures)
The company calls itself one of India's leading fully integrated crop protection and nutrition companies. It cites a portfolio of 20+ technical products and 130+ formulations, ownership of the "Tractor Brand", plants at Chopanki (Rajasthan), Samba and Udhampur (Jammu & Kashmir) and Dahej (Gujarat), and an upcoming facility at Sotanala (Rajasthan). It highlights technical synthesis plants at Chopanki and Dahej as a backward-integration advantage. It also describes in-house R&D, farmer education through the IIL Foundation, and a pan-India reach of 7.5 million+ farmers, 70,000+ dealers and 8,500+ distributors (Press Release, Q1 FY27, 11 Aug 2026).
Business model and revenue model
| Revenue channel | Description | Share of FY2026 revenue | Economics |
|---|---|---|---|
| B2C (branded formulations) | Branded crop-protection products sold through the distributor → retailer → farmer chain under Tractor Brand and sub-brands | 73% | Highest gross margin; premium sub-portfolio (Focus Maharatna + Maharatna) equals 58% of B2C |
| B2B (institutional) | Sale of technicals and bulk formulations to other agrochemical formulators and marketers | 22% | Lower margin; used to absorb plant capacity and meet top-line goals in weak B2C seasons |
| Exports | Technicals and formulations to ~22 countries on the back of ~182 international registrations, including from a 100% export-oriented SEZ formulation unit at Dahej | 5% | Early-stage; management targets ~10% share over 2–3 years |
Revenue model characterisation: About 100% product sales. There is no material service, subscription or licensing revenue. In-licensing runs the other way: IIL pays partners such as Nissan and Corteva for the rights to market their molecules. In-licensed product revenue was about INR 46 crore in Q1 FY27 versus about INR 36 crore in Q1 FY26 (Q1 FY27 earnings call, per secondary summaries).
Product category mix (B2C revenue, FY2026)
| Category | Share | Function |
|---|---|---|
| Insecticides | 49% | Insect control in crops |
| Herbicides | 37% | Weed prevention and control |
| Fungicides | 10% | Fungal disease control |
| Biologicals / PGR | 4% | Crop health and productivity |
Customer types and end-markets
End-users: Smallholder and mid-size Indian farmers growing paddy, wheat, cotton, maize, soybean, chilli, pulses, vegetables and horticulture crops.
Direct customers: About 8,500 distributors (B2C), Indian and global agrochemical companies (B2B), and importers and distributors in about 22 countries (exports).
Seasonality: Revenue is heavily skewed to the kharif (monsoon) season. Q1 (Apr–Jun) and Q2 (Jul–Sep) together produced about 62% of FY2026 revenue (INR 1,329 crore of INR 2,140 crore).
Independent characterisation
IIL is best described as a branded-generics domestic formulator that is moving into in-licensed specialty molecules and selective backward integration. It does not discover proprietary molecules at scale, unlike PI Industries or the multinationals. Its OAT Agrio JV is a discovery effort, but it has no disclosed commercial new chemical entity yet. Its competitive moat is distribution depth and brand familiarity in north and central India, plus cost advantage from captive technicals. The strategic thesis since FY2023 has been margin repair through mix. Gross margin rose from 23.1% (FY23) to 31.5% (FY26) as the premium share of B2C climbed from 51% to 58%. The thesis faced a stress test in FY2026–Q1 FY27: weather-driven demand weakness forced a higher B2B mix, and management cut guidance.
Strategy
Stated strategy themes (paraphrased from the Q1 FY27 deck and FY26 calls)
| Pillar / shift | Content |
|---|---|
| Innovative product portfolio | Premiumisation; aggressive launches; patented and in-licensed chemistries |
| Brand equity & farmer connect | Tractor Brand; ICS plots; field days; digital farmer campaigns |
| FMCG-like distribution | 8,500+ distributors, 70,000+ retailers, 750+ sales and marketing staff, 1,200+ crop advisors |
| Manufacturing prowess | Integrated technical + formulation; ~95% in-house revenue |
| Complete crop solution | Crop-based portfolio building (rice, cotton, chilli, soybean, maize, wheat) |
| Enhanced market presence | Kaeros as second channel; exports |
The company frames its strategy around four "fundamental pillars" and six "internal shifts":
Forward-looking themes in the deck: innovation edge, diversified growth engines (international collaborations, Kaeros, global business), global expansion, operational excellence, a business model less dependent on rainfall, and disciplined value creation.
Strategic initiatives (last 24 months)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Corteva Agriscience collaboration | Aug 2025 onward | SPARCLE (Aug 2025), GRANUVIA (May 2026), Spinoace (Q1 FY27) | Active; GRANUVIA FY27 target about INR 20 crore gross |
| Nissan Chemical partnership extension | May 2025 | Altair paddy herbicide | Active |
| Kaeros Research acquisition | Nov 2024 | Independent dealer channel; direct imports; Dr Dada brand | Management targeted ~INR 100 crore business in FY27 and 5–8% of volumes |
| Dahej capacity expansion | Commercial June 2025 | ~INR 150 crore capex; management expected ~INR 100 crore revenue contribution in FY26 | Ramping |
| Sotanala greenfield | 2025–2027 | Fully automated formulation + technical plant; ~INR 200 crore total | Formulation ~Oct–Nov 2026; technical ~Mar–Apr 2027 |
| Digitalisation | FY24–FY26 | IIL 360, IIL Pariwar, IIL Humsafar CRM; IIL GrowSmart learning | Implemented |
| Demand generation | FY26 | 10,000+ demos; 26,000+ farmer meetings; 6,500+ field days; 1,45,000+ farmer visits on field days | Ongoing; Q1 FY27: 3,600+ meetings, 600+ field days, 1,400 demos, 15,000+ farmer visits |
| ICS programme expansion | FY27 | Double from 36 plots; 4 crops; 14 states | Announced Aug 2026 |
| Capital allocation discipline | Q3–Q4 FY26 | Non-essential capex frozen; investment decisions gated on ROCE/ROE; maintenance capex INR 25–30 crore after FY27 projects | Active |
| Working-capital reduction | FY25–FY27 | Earlier target to cut cycle 20–25 days; FY27 finance-cost reduction target 25–30% | Not yet achieved (FY26 NWC 168 days) |
| ESPS 2026 | May 2026 | Up to 2,00,000 shares for employees | Pending shareholder approval |
| Sustainability | FY26 | ~40% renewable energy; ZLD at 3 plants; Project Green Miyawaki forests | Ongoing |
Management guidance and medium-term targets
| Target | Original | Revised / latest | Source |
|---|---|---|---|
| FY26 revenue growth | ~10% (double-digit ambition) | 5–6%; actual 7% | Q4 FY25 call; ~Feb 2026 revision |
| FY26 premium (B2C) growth | ≥20% | ~10% | Same |
| FY26 operating margin | ~9% (per TradeBrains summary) | ~7% | Same; actual EBITDA margin 10.6% (definitions differ) |
| Premium share of B2C | 65% within 1–2 years (stated FY25) | 58% in FY26; 64% in Q1 FY27 | Calls; deck |
| New launches | ≥6 per year | >25 in three years | Calls |
| Exports share | ~10% in 2–3 years | 5% (FY26) | Q4 FY26 call |
| FY27 top-line and bottom-line | Positive growth, double-digit volume ambition | Q1 FY27 down 12% / 24%; management "confident of progressively building momentum" | Q4 FY26 call; Q1 FY27 PR |
| FY27 finance costs | Down 25–30% | — | Q1 FY27 commentary (secondary) |
| Maintenance capex post-FY27 | INR 25–30 crore a year | — | Q4 FY26 call |
Products & Services
IIL markets 130+ formulations and 20+ technicals. Not every SKU is publicly described. Products are listed below where a public source names them. Active ingredients are given only where verified; otherwise "not disclosed in sources reviewed".
Master brand
| Brand | Description | Notes |
|---|---|---|
| Tractor Brand | Umbrella trademark on most B2C products; brand heritage since 1986; acquired 10 Mar 2003 | Brand campaign tagline positions it as the pride of the country and the identity of the farmer (Hindi slogan) |
| Dr Dada (Kaeros) | Brand of Kaeros Research; positioned as the story of a young scientist who is a farmer's son | Built to create an independent dealer channel separate from Tractor Brand distributors |
Partnership / premium launches (chronological)
| Product | Category | Partner / origin | Launch | Target crop / pest | Key facts |
|---|---|---|---|---|---|
| Nissan fungicide (#1 brand claim) | Fungicide | Nissan Chemical, Japan; exclusive Indian marketing rights | 2,012 | Not specified in extracted text | Company says #1 fungicide brand (management estimate) |
| Green Label | Herbicide | Make in India; IIL makes technical and formulation | Pre-2016 | Paddy | Bispyribac Sodium 10% SC; first in India to manufacture both technical and formulation |
| Paddy herbicide (Make in India) | Herbicide | IIL | 2,016 | Paddy | Claimed #2 in paddy herbicide category |
| In-house insecticide | Insecticide | Developed by IIL | 2,018 | Multi-crop | Claimed top-10 in insecticides |
| Patented herbicide (Nissan technical collaboration) | Herbicide | IIL with Nissan | 2,021 | Not specified | Claimed top-10 in herbicides |
| Shinwa | Insecticide (premium) | Nissan, Japan | 2,022 | Not specified | Maharatna portfolio |
| Izuki | Not specified | Nissan, Japan | 2,022 | Not specified | Launched with Shinwa |
| Patented Nissan novel insecticide | Insecticide | Nissan; co-exclusive marketing rights in India | 2,022 | Label claim on 6 crops | Claimed top-4 in insecticides |
| Torry | Herbicide | Make in India | 2,022 | Maize | Claimed 3rd biggest corn herbicide |
| "Top-3 performer" Make in India product | Not specified | IIL | 2,022 | Not specified | Per presentation |
| Torry Super | Herbicide (post-emergence) | IIL ("SPF technology") | 4 Oct 2024 | Maize | Extension of Torry franchise |
| Centran | Insecticide | Not specified | 6 Jan 2025 | Not specified | Management cited it among strong FY26 performers |
| Altair | Herbicide | Nissan Chemical Corporation | 26 May 2025 | Paddy | FY26 launch |
| SPARCLE | Insecticide | Corteva Agriscience | 11 Aug 2025 | Paddy; brown plant hopper | First Corteva collaboration product |
| GRANUVIA | Insecticide (granular) | Developed by Corteva Agriscience; marketed by IIL | 16 May 2026 | Paddy; brown plant hopper and stem borer | About INR 5 crore sales in Q1 FY27; management expects ~INR 20 crore gross sales in FY27 |
| Spinoace | Insecticide | Corteva collaboration | Q1 FY27 | Not specified | Management expects INR 10 crore+ in FY27 |
Launch cadence: More than 25 products launched in the three years to FY26 (Q4 FY26 call). Five launches in 9M FY26. The company said it had visibility to launch about five more in the 2026 kharif season.
Named brands in the generic and established portfolio
| Brand | Category | Public detail |
|---|---|---|
| Lethal / Lethal Super 550 | Insecticide | Maharatna brand |
| Hercules | Insecticide | Maharatna brand |
| Hachiman | — | Maharatna brand |
| Pulsor | — | Named in company product list |
| Hakama | — | Named in company product list |
| Kunoichi | Insecticide | Named product |
| Mission SC | Insecticide | Named product |
| Bheema / Bheema Plus | Insecticide | Named products |
| Milthion | Insecticide | Named product |
| Metacil | Insecticide | Named product |
| Turner | Insecticide | Named product |
| Supremo SP | Insecticide | Named product |
| Dominant | Insecticide | Named product |
| Encounter | Insecticide | Named product |
| Sargent SC | Insecticide | Named product |
| Super Star | Insecticide | Named product |
Brand list per ROIC.ai/S&P-derived company description and Screener. Active ingredients and specifications not disclosed in sources reviewed. Pricing for all products: not publicly disclosed. Indian agrochemicals use MRP-based retail pricing with distributor and retailer margins and seasonal schemes.
Technicals and B2B products
More than 20 technical-grade active ingredients are made at the Chopanki and Dahej multi-purpose plants (20 production streams). Individual technical molecules other than Bispyribac Sodium are not listed in reviewed sources. B2B customers buy technicals and bulk formulations.
Biologicals, PGR and nutrition
Biologicals and PGRs are about 4% of B2C. A biological unit at Shamli (Uttar Pradesh) is shown on the manufacturing map. Biological R&D covers bio-pesticides, bio-fertilisers and nano-technology products. A household-pesticide range is referenced historically in company background notes.
Services (non-revenue)
IIL Crop Solutions (ICS) programme: 36 demonstration plots across rice, cotton, chilli and soybean in 14 states. Plan is to double the number of plots.
Digital platforms: IIL 360 (field-force app), IIL Pariwar (distributor app), IIL Humsafar (retailer platform), IIL GrowSmart (employee learning).
Financial Narrative
Primary source: Q1 FY27 investor presentation (historical highlights), FY26 consolidated P&L in the same deck, Screener consolidated statements (FY22–FY25), and StockAnalysis (balance sheet and cash flow, INR million converted to crore). All figures are consolidated INR crore unless noted.
Income statement
Notes: EPS diluted equals basic; there are no material dilutive instruments. The ESPS 2026 is pending. FY22–FY24 DPS are derived from Screener payout ratios and the dividend record (INR 3 final dividends historically), so treat them as approximate. FY26 other income was INR 11.7 crore and associate share INR 0.3 crore.
Margin profile
Growth rates (FY2022→FY2026, derived): Revenue CAGR 9.2%; gross profit CAGR 14.2%; EBITDA CAGR 7.5%; PAT CAGR 6.8%.
Quarterly run-rate (most recent five quarters)
Q4 FY26 revenue is derived: FY26 INR 2,140.0 crore less 9M INR 1,713.75 crore. That implies about 19% YoY growth against Q4 FY25 (~INR 359 crore), matching management's comment of roughly 19% Q4 growth. One aggregator reported Q4 FY26 revenue of INR 430 crore down 15.7% YoY, which conflicts with company data and appears erroneous. Q2 FY26 EBITDA is derived from H1 FY26 EBITDA of INR 174.06 crore less Q1, giving about INR 89.5 crore (14.0%). That figure is left blank in the table because it is not directly reported. Q4 FY26 EBITDA margin of about 6.0% is per an aggregator.
Balance sheet
Notes: FY2026 total assets (~INR 2,000 crore) and equity (~INR 1,213 crore) are derived. Equity uses book value per share of about INR 416–417 × 2.91 crore shares; total assets sum the StockAnalysis components. PP&E including CWIP was INR 477 crore in FY26 versus INR 426 crore in FY25 (StockAnalysis). Goodwill is not separately material or disclosed. Debt is short-term working-capital borrowing; there is no disclosed long-term debt. Management-reported net working capital days are shown in 6.6.
Cash flow
Dividends paid are not separately verified for each year. They are small, roughly INR 6–9 crore a year, consistent with a ~INR 2–3 DPS on about 2.9–3.0 crore shares.
Ratios
ROE and ROCE are company-reported (Q1 FY27 deck); 3-year improvement: ROCE +570 bp and ROE +450 bp from FY23. ROIC is not separately disclosed; ROCE is the closest proxy.
Commentary on trends, inflections and drivers
FY2022–FY2023, the margin trough. Revenue jumped 19.8% in FY23 to INR 1,801 crore, but gross margin collapsed 330 bp to 23.1% and EBITDA margin halved to 6.8%. The drivers were a post-COVID spike in Chinese technical prices, inventory build at peak cost (inventory up INR 232 crore; OCF negative INR 11 crore), and a commodity-heavy mix where premium was only 51% of B2C. Net debt rose to INR 143 crore, the highest in the period.
FY2024–FY2025, mix-led repair. Management de-prioritised B2B, which fell from 27% to 20% of mix, and pushed Maharatna products. Gross margin expanded 650 bp in FY25 to 32.0% on flat revenue (+1.7%). PAT reached a record INR 142 crore. FY24 OCF was a strong INR 187 crore as inventory unwound. In FY25, receivables and inventory rose again (NWC days up to 172), cutting OCF to INR 93 crore, and the INR 50 crore buyback was executed.
FY2026, top-line recovery but margin plateau. Revenue grew 7% to INR 2,140 crore, against original guidance of about 10% that was later cut to 5–6%. Gross margin held near 31.5%, but EBITDA margin slipped 50 bp to 10.6%. Employee costs rose (INR 164 crore) and other expenses rose (INR 284 crore) with heavier marketing and launch spend. H2 was very weak: Q3+Q4 PAT was INR 22 crore. Finance cost more than doubled to INR 16.9 crore on higher working-capital borrowing (debt INR 157 crore), and receivables climbed to INR 487 crore as the company extended channel credit. Capex of about INR 95 crore (Dahej, Sotanala) plus OCF of INR 100 crore left free cash flow near zero.
Q1 FY27, weather shock. Revenue fell 12% YoY to INR 612 crore on a rainfall deficit and a delayed kharif. Volume was down about 13% per a ScanX call summary. Gross margin still expanded 240 bp to 31.6% through price discipline and a higher premium share of B2C (64%). EBITDA fell 20% and PAT fell 24% as fixed costs deleveraged; employee expense rose 14% YoY to INR 47.3 crore.
Key inflection to monitor: Whether Sotanala and Dahej capacity plus in-licensed launches (GRANUVIA, Spinoace, SPARCLE, Altair) can return the business to double-digit growth without further working-capital stretch. Management told investors to expect finance costs to fall 25–30% in FY27.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Holding | Role |
|---|---|---|---|
Insecticides (India) Limited | Parent | — | Manufacturing, marketing, exports |
Kaeros Research Pvt Ltd (presented as "Kaeros Research Limited") | Wholly owned subsidiary | 100% | Acquired FY25; independent dealer ecosystem and second distribution channel (brand "Dr Dada"); holds import licences and vendor approvals |
IIL Biologicals Limited | Wholly owned subsidiary | 100% | Biologicals platform |
OAT & IIL India Laboratories Pvt Ltd | Joint venture with OAT Agrio Co. Ltd (Japan) | 20% | New-molecule discovery R&D at Chopanki |
IIL Overseas DMCC (Dubai) | Former WOS | 100% (dissolution approved 9 Aug 2024) | Being wound up |
IIL Foundation | CSR vehicle | — | Farmer education, Project Green |
Revenue by Segment
| Segment (INR Cr, derived) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
B2C revenue (INR Cr) | 1,357 | 1,500 | 1,562 |
B2B revenue (INR Cr) | 511 | 400 | 471 |
Export revenue (INR Cr) | 98 | 100 | 107 |
Total revenue from operations (INR Cr) | 1,966 | 2,000 | 2,140 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
B2C share (%) | 65 | 68 | 69 |
B2B share (%) | 26 | 27 | 26 |
Exports share (%) | 9 | 5 | 5 |
Segment YoY growth (%, derived)
| Segment YoY growth (%, derived) | FY2025 | FY2026 |
|---|---|---|
B2C growth (%) | 10.5 | 4.1 |
B2B growth (%) | -21.7 | 17.7 |
Exports growth (%) | 2.0 | 7.0 |
Revenue by Segment (%)
| B2C mix (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Premium (Focus Maharatna + Maharatna) share of B2C (%) | 51 | 51 | 59 | 57 | 58 |
Generic share of B2C (%) | 49 | 49 | 41 | 43 | 42 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansB2C category share (%)
| B2C category share (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Insecticides (%) | 53 | 45 | 45 | 49 | 49 |
Herbicides (%) | 33 | 40 | 33 | 37 | 37 |
Fungicides (%) | 11 | 11 | 19 | 10 | 10 |
Biologicals & PGR (%) | 3 | 4 | 3 | 4 | 4 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 1,504 | 1,801 | 1,966 | 2,000 | 2,140 |
Revenue growth YoY (%) | 5.9 | 19.8 | 9.2 | 1.7 | 7.0 |
Gross profit (INR Cr) | 397 | 416 | 501 | 641 | 675 |
EBITDA (INR Cr) | 170 | 122 | 163 | 221 | 227 |
Depreciation & amortisation (INR Cr) | 26 | 26 | 29 | 29 | 36 |
Finance cost (INR Cr) | 7 | 13 | 11 | 7 | 17 |
Profit before tax (INR Cr) | 141 | 84 | 132 | 193 | 187 |
Net profit / PAT (INR Cr) | 107 | 63 | 102 | 142 | 139 |
EPS basic (INR, bonus-adjusted) | 36.29 | 21.36 | 34.59 | 47.98 | 47.91 |
Dividend per share (INR, bonus-adjusted, approx.) | 2 | 3 | 3 | 2 | 2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 26.4 | 23.1 | 25.5 | 32.0 | 31.5 |
EBITDA margin (%) | 11.3 | 6.8 | 8.3 | 11.1 | 10.6 |
PBT margin (%) | 9.4 | 4.7 | 6.7 | 9.7 | 8.7 |
Net margin (%) | 7.1 | 3.5 | 5.2 | 7.1 | 6.5 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric (INR Cr) | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 691.1 | 637.7 | 384.9 | 426.3 | 611.5 |
Gross profit (INR Cr) | 201.7 | 219.7 | — | 128.9 | 193.2 |
EBITDA (INR Cr) | 84.6 | — | 25.3 | — | 67.6 |
PAT (INR Cr) | 58.1 | 59.1 | 10.5 | 11.7 | 43.9 |
Gross margin (%) | 29.2 | 34.5 | — | 30.2 | 31.6 |
EBITDA margin (%) | 12.2 | — | 6.6 | 6.0 | 11.1 |
Balance Sheet
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 1,396 | 1,696 | 1,714 | 1,898 | 2,000 |
Cash & short-term investments (INR Cr) | 36 | 20 | 65 | 67 | 92 |
Total debt (INR Cr) | 54 | 163 | 87 | 105 | 157 |
Net debt (INR Cr) | 18 | 143 | 22 | 38 | 65 |
Shareholders' equity (INR Cr) | 870 | 919 | 1,014 | 1,085 | 1,213 |
Other intangible assets (INR Cr) | 11 | 13 | 14 | 14 | 19 |
Inventory (INR Cr) | 630 | 862 | 807 | 886 | 780 |
Trade receivables (INR Cr) | 289 | 296 | 297 | 385 | 487 |
Net fixed assets ex-CWIP (INR Cr) | 253 | 263 | 284 | 287 | — |
Capital work-in-progress (INR Cr) | 91 | 123 | 142 | 156 | — |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 135 | -11 | 187 | 93 | 100 |
Capital expenditure (INR Cr) | 67 | 87 | 49 | 37 | 95 |
Free cash flow (INR Cr) | 68 | -98 | 138 | 56 | 5 |
Change in inventory (INR Cr, cash impact) | 31 | -232 | 54 | -79 | 106 |
Change in receivables (INR Cr, cash impact) | -39 | -7 | -3 | -94 | -101 |
Buyback outflow (INR Cr) | — | — | — | 50 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 12.4 | 6.9 | 10.1 | 13.1 | 11.4 |
ROCE (%) | 16.7 | 10.4 | 13.6 | 17.8 | 16.1 |
ROA (%, derived) | 7.7 | 3.7 | 6.0 | 7.5 | 7.0 |
Debt to equity (x, derived) | 0.06 | 0.18 | 0.09 | 0.10 | 0.13 |
Net debt to EBITDA (x, derived) | 0.11 | 1.17 | 0.14 | 0.17 | 0.29 |
Interest coverage EBITDA/interest (x, derived) | 24.3 | 9.4 | 14.8 | 31.6 | 13.4 |
Asset turnover (x, derived) | 1.08 | 1.06 | 1.15 | 1.05 | 1.07 |
Net working capital days (company) | 162 | 169 | 151 | 172 | 168 |
Cash conversion cycle days (Screener) | 181 | 178 | 161 | 172 | — |
Inventory days (Screener) | 228 | 247 | 220 | 238 | — |
Debtor days (Screener) | 70 | 60 | 55 | 70 | — |
Payable days (Screener) | 117 | 128 | 114 | 136 | — |
Revenue by Region
| Geography (INR Cr, derived) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
India domestic revenue (INR Cr) | 1,369 | 1,711 | 1,868 | 1,900 | 2,033 |
Export revenue (INR Cr) | 135 | 90 | 98 | 100 | 107 |
Geography growth YoY (%, derived)
| Geography growth YoY (%, derived) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
India domestic growth (%) | 25.0 | 9.2 | 1.7 | 7.0 |
Export growth (%) | -33.4 | 8.9 | 2.0 | 7.0 |
Channel Details
| Channel | Domestic | Export |
|---|---|---|
B2C | ~INR 1,562 crore (100% domestic) | — |
B2B | ~INR 471 crore | — |
Exports (technical + formulation) | — | ~INR 107 crore |
Capital Markets
| Item | Value | Date / source |
|---|---|---|
Last verified close | INR 611.70 | 23 Sep 2026 (Anand Rathi) |
52-week range | INR 525.90 – INR 787.00 | Anand Rathi, Sep 2026 |
All-time high (post-bonus) | ~INR 1,098 | Jul 2025 (MarketScreener 1-yr high as of mid-2026) |
1-year return | about −19.4% | Anand Rathi, 23 Sep 2026 |
3-year return | about +29.7% (cumulative, as reported; another snapshot on 28 Aug 2026 showed +8.7%) | Anand Rathi |
5-year return | Not reliably verified for the current date. Screener showed a 27% 5-year CAGR as of mid-2025, before the 2025–26 drawdown. | Screener (dated) |
YTD 2026 | about −13.9% (to 4 Sep 2026) | MarketScreener |
Capital Markets Data (INR) and Market Valuation
| Metric | Jun-2025 | Jul-2025 | Aug-2025 | Sep-2025 | Oct-2025 | Nov-2025 | Dec-2025 | Jan-2026 | Feb-2026 | Mar-2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Month-end close (INR) | 965.70 | 1,072.55 | 827.60 | 748.35 | 716.95 | 724.20 | 714.25 | 590.75 | 620.55 | 531.45 |
Month-end market cap (INR Cr) | 2,810 | 3,121 | 2,408 | 2,178 | 2,086 | 2,107 | 2,078 | 1,719 | 1,806 | 1,546 |
Valuation Multiples
| Multiple | IIL | Basis |
|---|---|---|
Market cap | ~INR 1,780 crore | 2.91 crore shares |
Enterprise value | ~INR 1,845 crore | Plus FY26 debt INR 157 crore, less cash and ST investments INR 92 crore |
P/E (TTM) | ~14.2x | TTM EPS INR 43.02 (FY26 47.91 − Q1FY26 19.97 + Q1FY27 15.08) |
P/E (FY26) | ~12.8x | FY26 EPS INR 47.91 |
EV/EBITDA (TTM) | ~8.8x | TTM EBITDA ~INR 210 crore |
EV/Sales (TTM) | ~0.90x | TTM revenue ~INR 2,061 crore |
P/B | ~1.47x | BVPS ~INR 416 |
Dividend yield | ~0.3% | INR 2 DPS |
Dividend History
| Fiscal year | Dividend (INR/share) | Type | Notes |
|---|---|---|---|
FY2022 | 3 (pre-bonus) | Final | Record 16 Sep 2022 |
FY2023 | 3 (approx.) | Interim | Ex-date 24 Feb 2023 |
FY2024 | 2–3 (approx.) | Interim | Ex-date 10 Nov 2023 |
FY2025 | 2 | Interim, treated as final | Ex-date 23 Aug 2024 |
FY2026 | 2 | Interim | — |
Key Events
| Event | Date | Detail |
|---|---|---|
Bonus 1:2 | Apr 2015 | Record date 17 Apr 2015 |
Bonus 1:2 | Oct 2022 | Record date 3 Oct 2022; 98.66 lakh shares |
Buyback | Sep 2024 | INR 50 crore; 5 lakh shares at INR 1,000 (tender) |
Capital reduction FY2022 | FY2022 | — |
Active buyback authorisation | — | As of Oct 2026 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
CRISIL | Long-term bank facilities (INR 690 crore total rated) | A+ | Stable | Upgraded 17 Jun 2025; reaffirmed 9 Jul 2025 and 16 Apr 2026 |
CRISIL | Short-term bank facilities | A1 | — | Reaffirmed |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance (latest)
-
FY27: return to positive top-line and bottom-line growth, aiming for double-digit volume, with momentum "progressively building" after a weak Q1.
-
New launches: GRANUVIA (~INR 20 crore) and Spinoace (INR 10 crore+) in FY27; about five more kharif launches expected.
-
Kaeros: about INR 100 crore business target in FY27 (set in Aug 2025).
-
Finance cost down 25–30% in FY27; maintenance capex INR 25–30 crore a year once Sotanala is complete.
-
Premium mix ambition of 65% of B2C; exports to ~10% of sales in 2–3 years.
Consensus growth expectations
Not reliably available. The stale Simply Wall St consensus assumes about 14.6% revenue CAGR, which looks aggressive against the FY26 actual of 7% and Q1 FY27 at −12%.
Bull case
-
Mix-driven earnings power: Gross margin held at 31.6% even as revenue fell 12% in Q1 FY27. If volumes normalise, EBITDA margins could return to 11–12%. On about INR 2,300 crore of revenue that would mean INR 255–275 crore of EBITDA, versus about INR 210 crore TTM.
-
Cheap valuation: About 14x TTM P/E, about 8.8x EV/EBITDA and about 1.5x book. The stock is roughly 44% below its July 2025 high and close to its 52-week low, despite a CRISIL A+ balance sheet and 11–13% ROE.
-
Visible capacity and pipeline catalysts: Sotanala formulation (late 2026) and technical (2027), a Corteva and Nissan launch cadence, and the Kaeros second channel offer multiple growth levers that are not priced in.
Bear case
-
Working-capital drag erodes cash returns: NWC of 168 days, receivables up 26% and FY26 FCF of about INR 5 crore mean reported profits are not converting to cash. Further channel-credit expansion would raise credit risk.
-
Guidance credibility gap: FY26 guidance was halved and Q1 FY27 missed sharply. Weather dependence persists despite the claim of a more resilient model.
-
Structural margin gap versus peers: Operating margin is about 6 pp below Dhanuka. The generic and B2B mix (42% of B2C is generic; B2B was 34% of Q1 FY27) keeps IIL exposed to Chinese price deflation, and in-licensing royalties limit upside on premium products.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Nov 2026 | Q2 FY27 results: kharif recovery, B2B/B2C mix, receivables trajectory |
| Oct–Nov 2026 | Sotanala formulation commissioning |
| Rabi 2026-27 | Wheat-herbicide demand; ramp of Corteva products |
| Feb 2027 | Q3 FY27; FY28 guidance tone |
| Mar–Apr 2027 | Sotanala technical-plant start |
| May 2027 | FY27 results: delivery against finance-cost, Kaeros and export targets; ESPS implementation |
| Ongoing | Monsoon 2027 forecast (IMD, April 2027); Chinese technical price trends; CRISIL rating review |
Concluding analyst verdict
Insecticides (India) Limited is a fundamentally sound but cyclically challenged mid-cap Indian agrochemical franchise, now going through a credibility test. Its achievements over FY2023–FY2025 are real. Gross margin rose by more than 8 percentage points, ROCE recovered from 10.4% to roughly 16–18%, and the company assembled credible partnerships with Nissan and Corteva that give it access to patented chemistry without discovery risk. The balance sheet remains conservative, with debt to equity around 0.13x and an A+ rating. The Tractor Brand and its distribution network remain hard assets that a new entrant could not easily replicate.
Two issues, however, prevent the business from earning a structurally higher valuation. The first is cash conversion. Over five years cumulative free cash flow was only about INR 170 crore, against about INR 553 crore of cumulative PAT, consumed by inventory, receivables and capex. Until net working capital falls well below 150 days, reported growth will not translate into compounding cash. The second is the volatility of earnings and guidance. The FY26 reset and the weak Q1 FY27 show that "premiumisation" has improved unit economics but has not insulated the business from monsoon swings or forced a lower-margin B2B mix.
At about 14x trailing earnings and about 1.5x book, the market is already pricing low growth, so the risk-reward looks asymmetric to the upside if FY27 delivers even modest recovery. The validation points are kharif normalisation, a scaled Corteva portfolio and the Sotanala start-up. Our synthesis is neutral-to-constructive. Conviction should be gated on three verifiable milestones by mid-2027: positive H2 FY27 PAT growth, FY27 operating cash flow above INR 150 crore, and finance costs actually falling as guided. Failure on these would confirm the bear thesis that IIL is a sub-scale, working-capital-heavy formulator whose margin gains are cyclical rather than structural.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Category | Tenure / notes |
|---|---|---|---|
Hari Chand (H.C.) Aggarwal | Chairman | Promoter, Executive | Founder; recognised by CropLife as an industry stalwart. |
Rajesh Kumar Aggarwal | Managing Director (referred to as MD & CEO in awards) | Promoter, Executive | On board since 31 Oct 2001; age ~55 (MarketScreener). Hurun India "Excellence in Family Business" award 2025. |
Sanskar Aggarwal | Whole-Time Director (Additional) | Promoter group, Executive | Appointed 28 May 2026 for 5 years, subject to shareholder approval; son of the MD |
Anil Kumar Goyal | Whole-Time Director | Executive | — |
Shyam Lal Bansal | Independent Director | Non-executive | — |
Supratim Bandyopadhyay | Independent Director | Non-executive | — |
Praveen Gupta | Independent Director | Non-executive | Woman director |
Anil Kumar Bhatia | Independent Director | Non-executive | — |
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Rajesh Kumar Aggarwal | MD | See above |
Sandeep Aggarwal | Chief Financial Officer | Leads investor calls |
Sandeep Kumar | Company Secretary & Chief Compliance Officer | Signatory to Aug 2026 filings |
Dushyant Sood | Chief Marketing Officer | Participated in Q4 FY25 call (May 2025) |
| — | Chief Operating Officer | Appointed 11 Nov 2025 per MarketScreener |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
11 Nov 2025 | New COO appointed | Operational strengthening amid slowing growth |
28 May 2026 | Nikunj Aggarwal resigned as Whole-Time Director with immediate effect | Promoter-family member and KMP |
28 May 2026 | Sanskar Aggarwal appointed WTD (Additional), 5-year term | Next-generation succession signal |
Shareholding Trend
| Holder category (%) | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|
Promoters & promoter group (%) | 72.30 | 72.30 | 72.30 | 72.30 | 72.30 |
Mutual funds (%) | 9.07 | 9.06 | 9.06 | 8.93 | 8.93 |
FII / FPI (%) | 4.66 | 4.51 | 4.46 | 4.50 | 4.40 |
Other DIIs (%) | 0.65 | 0.44 | 0.34 | 0.34 | 0.34 |
Retail & others (%) | 13.32 | 13.69 | 13.85 | 13.94 | 14.03 |
Major Shareholders
| Rank | Holder | Shares | Stake |
|---|---|---|---|
| 1 | Hari Chand Aggarwal (as The First Trustee, family trust) | 1,88,14,302 | 64.66% |
| 2 | HDFC Small Cap Fund | 25,98,408 | 8.93% |
| 3 | India Insight Value Fund | 9,24,000 | 3.18% |
| 4 | Sanskar Aggarwal (promoter group) | 4,00,000 | 1.37% |
| 5 | Rajesh Kumar Aggarwal (promoter) | 4,00,000 | 1.37% |
| 6 | Hari Chand Aggarwal (The First Trustee, separate trust) | 3,68,750 | 1.27% |
| 7 | ISEC Organics Limited (promoter group) | 3,53,964 | 1.22% |
| 8 | Hari Chand Aggarwal (The First Trustee, separate trust) | 3,00,000 | 1.03% |
| 9 | Hari Chand Aggarwal (The First Trustee, separate trust) | 2,00,000 | 0.69% |
| 10 | Hari Chand Aggarwal (individual) | 2,00,000 | 0.69% |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors |
|---|---|
Domestic branded B2C formulations | Dhanuka Agritech, Rallis India (Tata), Bayer CropScience India, Sumitomo Chemical India, Crystal Crop Protection (unlisted), Best Agrolife, Coromandel International (crop protection), UPL (Advanta/UPL SAS India), FMC India, Syngenta India, BASF India, Willowood (unlisted) |
Technicals / B2B | Bharat Rasayan, Meghmani Organics, Heranba Industries, India Pesticides, Astec LifeSciences, GSP Crop Science, NACL Industries |
In-licensing of MNC molecules | Dhanuka (with Nissan, Bayer, others), Rallis, PI Industries (CSM-led), Sumitomo India |
Exports | UPL, PI Industries, Sharda Cropchem, Meghmani, Bharat Rasayan |
Peer Comparison FY2026
| Metric | Insecticides India | Dhanuka Agritech | Rallis India |
|---|---|---|---|
Revenue (INR Cr) | 2,140 | 2,020 | 2,897 |
Revenue growth YoY (%) | 7.0 | -0.8 | 8.8 |
Gross margin (%) | 31.5 | 40.3 | — |
EBITDA / operating margin (%) | 10.6 | 16.8 | 12.5 |
PAT (INR Cr) | 139 | 287 | 184 |
Net margin (%) | 6.5 | 14.2 | 6.4 |



